Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery
NCT ID: NCT02617082
Last Updated: 2015-11-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
828 participants
OBSERVATIONAL
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
partial breast irradiation
partial breast irradiation
The prescription dose is 40.5Gy in 15 fractions in 3 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
partial breast irradiation
The prescription dose is 40.5Gy in 15 fractions in 3 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18\~65 years old
* Pathologically confirmed DCIS, low- or intermediate- grade DCIS: (lesions of ≤2.5 cm diameter, resection margins of at least 3 mm, nuclei grade: 1-2), high grade DCIS: (lesions of ≤1 cm diameter, resection margins of at least 3 mm, nuclei grade: 3)
* Treated with breast conserving surgery
* Tumor bed is labeled with Titanium clips
* No malignancy history
* ECOG score 0\~1
* Written informed consent
Exclusion Criteria
* invasive breast cancer
* Multicentric disease
* Patients underwent mastectomy
* Previous radiation therapy of breast
* Medical contraindication for radiotherapy
* Pregnant or nursing
* suspicious calcification after surgery
18 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xiaoli Yu
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaoli Yu, MD.PhD
Role: PRINCIPAL_INVESTIGATOR
Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xiaoli Yu, MD,PhD
Role: primary
Xiaofang Wang, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FDRT-BC004
Identifier Type: -
Identifier Source: org_study_id